QLT names CEO
Executive Summary
QLT acting CEO Robert Butchofsky will fill the top post permanently. After an extensive search, the board decided to appoint Butchofsky based on his performance as acting chief since September 2005. Butchofsky joined QLT in 1998 and is credited with launching and commercializing the company's lead drug, the age-related macular degeneration injection Visudyne (vertaporfin). He previously worked for Allergan...